-+ 0.00%
-+ 0.00%
-+ 0.00%
Gilead corrects Q2 2026 Europe Odefsey sales to $58 million
Share
Listen to the news
Gilead corrects Q2 2026 Europe Odefsey sales to $58 million
  • Gilead issued a corrected version of its second-quarter 2026 earnings release to fix an error in the product sales table.
  • Odefsey sales in Europe for the three months ended June 30, 2026 were revised to USD 58 million from USD 28 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending